<b>Note
2:Acquisitions</b><b> </b><p style="margin-top:12px;margin-bottom:0px; margin-left:4%"><font size="2" style="font-family:Times New Roman"><b><i>Samil Acquisition </i></b></font></p><p align="justify" style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">On July7, 2009, the Company and Samil Pharmaceutical Co. Ltd. entered into a joint venture, Samil Allergan Ophthalmic
Joint Venture Company (Samil) in Korea by integrating the Samil Eyecare division with the Companys Korean ophthalmology products. In addition, the Company paid approximately $16.7 million ($12.8 million, net of cash acquired) to Samil
Pharmaceutical Co. Ltd. to acquire the Companys joint venture investment and received a 50.005% stockholder interest (50% plus one share) in the joint venture. The acquisition was funded from cash and equivalents balances. The Company
accounted for the Samil acquisition as a business combination. </font></p><p align="justify" style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">In connection with the Samil acquisition, the
Company acquired assets with a fair value of $41.4 million, including goodwill of $23.0 million, intangible assets of $5.1 million, cash of $3.9 million and other assets of $9.4 million, and assumed liabilities of $8.1 million. The Company believes
the fair values assigned to the assets acquired and liabilities assumed were based on reasonable assumptions. </font></p><p style="margin-top:12px;margin-bottom:0px; margin-left:4%;padding-bottom:0px;"><font size="2" style="font-family:Times New Roman"><b><i>Aczone</i></b><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font><b><i> Asset Purchase </i></b></font></p><b><i>Aczone</i></b><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font><b><i> Asset Purchase </i></b><p align="justify" style="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><font size="2" style="font-family:Times New Roman">On July11, 2008, the Company completed the acquisition of assets related to <i>Aczone</i><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font> (dapsone)gel 5%, a topical treatment for acne vulgaris, from QLT USA, Inc. (QLT) for approximately
$150.0million. The acquisition was funded from cash and equivalents balances. The Company acquired QLTs right, title and interest in and to the intellectual property, assigned contracts, registrations and inventories related to
<i>Aczone</i><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font>, which is approved for sale in both the United States and Canada for the treatment of certain
dermatological conditions. The Company accounted for the acquisition as a purchase of net assets. </font></p><i>Aczone</i><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font><i>Aczone</i><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font><p align="justify" style="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><font size="2" style="font-family:Times New Roman">The Company determined that the assets acquired consist of product rights for developed technology for <i>Aczone</i><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font> of $145.6 million and inventories of $4.4 million. The useful life of the developed technology was determined to be approximately eight years. The Company believes
the fair values assigned to the assets acquired were based on reasonable assumptions. </font></p><i>Aczone</i><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><p align="center" style="margin-top:0px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman">F-15 </font></p><p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/><h5 align="left"><a href="#toc">Table of Contents</a></h5><p align="center" style="margin-top:0px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman"><b>ALLERGAN, INC. </b></font></p><p align="center" style="margin-top:6px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS  (Continued) </b></font></p><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><p style="margin-top:0px;margin-bottom:0px; margin-left:4%"><font size="2" style="font-family:Times New Roman"><b><i>Esprit Acquisition </i></b></font></p><p align="justify" style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">On October16, 2007, the Company completed the acquisition of Esprit, a pharmaceutical company based in the United
States with expertise in the genitourinary market, for an aggregate purchase price of approximately $370.8million, net of cash acquired. The acquisition was funded from cash and equivalents balances. Prior to and in anticipation of the
acquisition, the Company loaned Esprit $74.8million in August 2007, the proceeds of which were used by Esprit to fund a milestone payment to a third party and to repay certain outstanding obligations to third-party lenders. The loan was
secured by all of Esprits assets. The loan terms were at fair value. The loan and accrued interest of $0.9million were effectively settled upon the acquisition with no resulting gain or loss. The Company accounted for the Esprit
acquisition as a business combination. In connection with the Esprit acquisition, the Company acquired assets with a fair value of $525.4million and assumed liabilities of $154.6million. The Esprit acquisition provides the Company with a
dedicated urologics product line within its specialty pharmaceuticals segment. During 2009, the Company received $2.4 million related to a contractual purchase price adjustment, $2.3 million of which was recorded as a reduction to goodwill.
</font></p><p style="margin-top:12px;margin-bottom:0px; margin-left:4%"><font size="2" style="font-family:Times New Roman"><b><i>EndoArt SA Acquisition </i></b></font></p><p align="justify" style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">On February22, 2007, the Company completed the acquisition of EndoArt, a provider of telemetrically-controlled (or remote-controlled) implants used in the treatment of morbid
obesity and other conditions, for an aggregate purchase price of approximately $97.1million, net of cash acquired. The acquisition consideration was all cash, funded from the Companys cash and equivalents balances. The Company accounted
for the EndoArt acquisition as a business combination. In connection with the EndoArt acquisition, the Company acquired assets with a fair value of $98.5million and assumed liabilities of $1.4million. </font></p><p align="justify" style="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><font size="2" style="font-family:Times New Roman">In conjunction with the EndoArt acquisition, the Company recorded an in-process research and development
expense of $72.0million related to EndoArts <i>EasyBand</i><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font> Remote Adjustable Gastric Banding
System in the United States, which had not received approval by the U.S.Food and Drug Administration (FDA) as of the EndoArt acquisition date and had no alternative future use. </font></p><i>EasyBand</i><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font><p style="margin-top:12px;margin-bottom:0px; margin-left:4%"><font size="2" style="font-family:Times New Roman"><b><i>Cornal Acquisition </i></b></font></p><p align="justify" style="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><font size="2" style="font-family:Times New Roman">On January2, 2007, the Company completed the acquisition of Cornal, a health care company that develops, manufactures and markets dermal fillers, for an aggregate
purchase price of approximately $209.2million, net of $2.3million associated with the settlement of a pre-existing unfavorable distribution agreement. The Company recorded the $2.3million charge at the acquisition date to
effectively settle the pre-existing unfavorable distribution agreement between Cornal and one of the Companys subsidiaries, primarily related to distribution rights for <i>Juvderm</i><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font> in the United States. Prior to the acquisition, the Company also had a $4.4million payable to Cornal outstanding for products purchased
under the distribution agreement, which was effectively settled upon the acquisition. The Company accounted for the Cornal acquisition as a business combination. In connection with the Cornal acquisition, the Company acquired assets
with a fair value of $284.8million and assumed liabilities of $75.6million. As a result of the acquisition, the Company obtained the technology, manufacturing process and worldwide distribution rights for <i>Juvderm</i><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font>, <i>Surgiderm</i><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font> and certain other hyaluronic acid-based dermal fillers. The acquisition was funded from the Companys cash and equivalents balances and its committed long-term
credit facility. During 2009, the Company received $9.2 million related to a contractual purchase price adjustment which was recorded as a reduction to goodwill. </font></p><i>Juvderm</i><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font><i>Juvderm</i><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font><i>Surgiderm</i><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><p align="center" style="margin-top:0px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman">F-16 </font></p><p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/><h5 align="left"><a href="#toc">Table of Contents</a></h5><p align="center" style="margin-top:0px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman"><b>ALLERGAN, INC. </b></font></p><p align="center" style="margin-top:6px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS  (Continued) </b></font></p><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><p style="margin-top:0px;margin-bottom:0px; margin-left:4%"><font size="2" style="font-family:Times New Roman"><b><i>Pro Forma Results of Operations </i></b></font></p><p align="justify" style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">The following unaudited <i>pro forma </i>operating results for the year ended December31, 2007 assume the Esprit
acquisition had occurred on January1, 2007, and exclude any <i>pro forma </i>charges for inventory fair value adjustments, share-based compensation expense and transaction costs. </font></p><i>pro forma </i><p style="font-size:10px;margin-top:0px;margin-bottom:0px"></p><table align="center" border="0" cellpadding="0" cellspacing="0" width="92%">
<tr>
<td width="81%"></td>
<td valign="bottom" width="12%"></td>
<td></td>
<td></td></tr>
<tr>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td align="center" colspan="2" style="border-bottom:1px solid #000000" valign="bottom"><font size="1" style="font-family:Times New Roman"><b>2007</b></font></td></tr>
<tr>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td align="center" colspan="2" valign="bottom"> <p align="center" style="margin-top:0px;margin-bottom:0px"><font size="1" style="font-family:Times New Roman"><b>(inmillions,except</b></font></p> <p align="center" style="margin-top:0px;margin-bottom:1px"><font size="1" style="font-family:Times New Roman"><b>pershareamounts)</b></font></p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Product net sales</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">3,911.9</font></td></tr>
<tr>
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Total revenues</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">3,971.8</font></td></tr>
<tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Earnings from continuing operations attributable to Allergan, Inc.</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">447.0</font></td></tr>
<tr>
<td colspan="4" valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Earnings per share from continuing operations attributable to Allergan, Inc. stockholders:</font></p></td></tr>
<tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Basic</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">1.47</font></td></tr>
<tr>
<td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Diluted</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">1.45</font></td></tr></table><tr>
<td width="81%"></td>
<td valign="bottom" width="12%"></td>
<td></td>
<td></td></tr><td width="81%"></td><tr>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td align="center" colspan="2" style="border-bottom:1px solid #000000" valign="bottom"><font size="1" style="font-family:Times New Roman"><b>2007</b></font></td></tr><td valign="bottom"><font size="1"></font></td><td valign="bottom"><font size="1"></font></td><td align="center" colspan="2" style="border-bottom:1px solid #000000" valign="bottom"><font size="1" style="font-family:Times New Roman"><b>2007</b></font></td><tr>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td align="center" colspan="2" valign="bottom"> <p align="center" style="margin-top:0px;margin-bottom:0px"><font size="1" style="font-family:Times New Roman"><b>(inmillions,except</b></font></p> <p align="center" style="margin-top:0px;margin-bottom:1px"><font size="1" style="font-family:Times New Roman"><b>pershareamounts)</b></font></p></td></tr><td valign="bottom"><font size="1"></font></td><td valign="bottom"><font size="1"></font></td><td align="center" colspan="2" valign="bottom"> <p align="center" style="margin-top:0px;margin-bottom:0px"><font size="1" style="font-family:Times New Roman"><b>(inmillions,except</b></font></p> <p align="center" style="margin-top:0px;margin-bottom:1px"><font size="1" style="font-family:Times New Roman"><b>pershareamounts)</b></font></p></td><p align="center" style="margin-top:0px;margin-bottom:0px"><font size="1" style="font-family:Times New Roman"><b>(inmillions,except</b></font></p><p align="center" style="margin-top:0px;margin-bottom:1px"><font size="1" style="font-family:Times New Roman"><b>pershareamounts)</b></font></p><tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Product net sales</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">3,911.9</font></td></tr><td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Product net sales</font></p></td><p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Product net sales</font></p><td valign="bottom"><font size="1"></font></td><td valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td><td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">3,911.9</font></td><tr>
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Total revenues</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">3,971.8</font></td></tr><td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Total revenues</font></p></td><p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Total revenues</font></p><td valign="bottom"><font size="1"></font></td><td valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td><td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">3,971.8</font></td><tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Earnings from continuing operations attributable to Allergan, Inc.</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">447.0</font></td></tr><td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Earnings from continuing operations attributable to Allergan, Inc.</font></p></td><p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Earnings from continuing operations attributable to Allergan, Inc.</font></p><td valign="bottom"><font size="1"></font></td><td valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td><td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">447.0</font></td><tr>
<td colspan="4" valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Earnings per share from continuing operations attributable to Allergan, Inc. stockholders:</font></p></td></tr><td colspan="4" valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Earnings per share from continuing operations attributable to Allergan, Inc. stockholders:</font></p></td><p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Earnings per share from continuing operations attributable to Allergan, Inc. stockholders:</font></p><tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Basic</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">1.47</font></td></tr><td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Basic</font></p></td><p style="margin-left:3.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Basic</font></p><td valign="bottom"><font size="1"></font></td><td valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td><td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">1.47</font></td><tr>
<td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Diluted</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">1.45</font></td></tr><td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Diluted</font></p></td><p style="margin-left:3.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Diluted</font></p><td valign="bottom"><font size="1"></font></td><td valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td><td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">1.45</font></td><p align="justify" style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">The
<i>pro forma </i>information is not necessarily indicative of the actual results that would have been achieved had the Esprit acquisition occurred on the indicated date, or the results that may be achieved in the future. </font></p><i>pro forma </i><p align="justify" style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">The Company does not consider the acquisitions of Samil, EndoArt or Cornal to be material business combinations,
either individually or in the aggregate. Accordingly, the supplemental <i>pro forma </i>operating results presented above do not include any adjustments related to these three acquisitions. </font></p><i>pro forma </i><p style="margin-top:12px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman"><b>Note3:Discontinued Operations </b></font></p><p align="justify" style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">On July2, 2007, the Company completed the sale of the ophthalmic surgical device business that it acquired as a part of the Cornal acquisition in January 2007, for
$28.6million. The net assets of the disposed business consisted of current assets of $24.3million, non-current assets of $9.8million and current liabilities of $4.2million. The Company recorded a pre-tax loss of
$1.3million ($1.0million net of tax) associated with the sale. </font></p><p align="justify" style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">The following amounts related to
the ophthalmic surgical device business have been segregated from continuing operations and reported as discontinued operations through the date of disposition. The Company did not account for its ophthalmic surgical device business as a separate
legal entity. Therefore, the following selected financial data for the Companys discontinued operations is presented for informational purposes only and does not necessarily reflect what the net sales or earnings would have been had the
business operated as a stand-alone entity. The financial information for the Companys discontinued operations includes allocations of certain expenses to the ophthalmic surgical device business. These amounts have been allocated to the
Companys discontinued operations on the basis that is considered by management to reflect most fairly or reasonably the utilization of the services provided to, or the benefit obtained by, the ophthalmic surgical device business. </font></p><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><p align="center" style="margin-top:0px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman">F-17 </font></p><p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/><h5 align="left"><a href="#toc">Table of Contents</a></h5><p align="center" style="margin-top:0px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman"><b>ALLERGAN, INC. </b></font></p><p align="center" style="margin-top:6px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS  (Continued) </b></font></p><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><p align="justify" style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">The following table sets forth selected financial data of the
Companys discontinued operations for 2007. </font></p><p style="margin-top:12px;margin-bottom:0px; margin-left:4%"><font size="2" style="font-family:Times New Roman"><b><i>Selected Financial Data for Discontinued Operations
</i></b></font></p><p style="font-size:12px;margin-top:0px;margin-bottom:0px"></p><table align="center" border="0" cellpadding="0" cellspacing="0" width="92%">
<tr>
<td width="87%"></td>
<td valign="bottom" width="10%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td align="center" colspan="2" valign="bottom"><font size="1" style="font-family:Times New Roman"><b>(inmillions)</b></font></td>
<td valign="bottom"><font size="1"></font></td></tr>
<tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Product net sales</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">20.0</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td></tr>
<tr>
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Loss from discontinued operations before income taxes</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">(1.1</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">)</font></td></tr>
<tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Loss from discontinued operations</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">(0.7</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">)</font></td></tr></table><tr>
<td width="87%"></td>
<td valign="bottom" width="10%"></td>
<td></td>
<td></td>
<td></td></tr><td width="87%"></td><tr>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td align="center" colspan="2" valign="bottom"><font size="1" style="font-family:Times New Roman"><b>(inmillions)</b></font></td>
<td valign="bottom"><font size="1"></font></td></tr><td valign="bottom"><font size="1"></font></td><td valign="bottom"><font size="1"></font></td><td align="center" colspan="2" valign="bottom"><font size="1" style="font-family:Times New Roman"><b>(inmillions)</b></font></td><td valign="bottom"><font size="1"></font></td><tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Product net sales</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">20.0</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td></tr><td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Product net sales</font></p></td><p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Product net sales</font></p><td valign="bottom"><font size="1"></font></td><td valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td><td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">20.0</font></td><td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td><tr>
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Loss from discontinued operations before income taxes</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">(1.1</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">)</font></td></tr><td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Loss from discontinued operations before income taxes</font></p></td><p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Loss from discontinued operations before income taxes</font></p><td valign="bottom"><font size="1"></font></td><td valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td><td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">(1.1</font></td><td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">)</font></td><tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Loss from discontinued operations</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">(0.7</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">)</font></td></tr><td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Loss from discontinued operations</font></p></td><p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Loss from discontinued operations</font></p><td valign="bottom"><font size="1"></font></td><td valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td><td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">(0.7</font></td><td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">)</font></td><p style="margin-top:12px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman"><b>Note4:Restructuring Charges and Integration Costs </b></font></p><p style="margin-top:12px;margin-bottom:0px; margin-left:4%"><font size="2" style="font-family:Times New Roman"><b><i>2009 Restructuring Plan
</i></b></font></p><p align="justify" style="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><font size="2" style="font-family:Times New Roman">On February4, 2009, the Company announced a restructuring plan that
involved a workforce reduction of approximately 460 employees, primarily in the United States and Europe. The majority of the employees affected by the restructuring plan were U.S. urology sales and marketing personnel as a result of the
Companys decision to focus on the urology specialty and to seek a partner to promote <i>Sanctura XR</i><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font>
to general practitioners, and marketing personnel in the United States and Europe as the Company adjusted its back-office structures to a reduced short-term sales outlook for some businesses. The restructuring plan also included modest workforce
reductions in other functions as the Company re-engineered its processes to increase efficiency and productivity. </font></p><i>Sanctura XR</i><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font><p align="justify" style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">As part of the restructuring plan, the Company modified the outstanding stock options issued in its February 2008 full-round employee stock option grant. The stock options were originally granted with an exercise price of $64.47 with a
standard four year graded vesting term, a ten year contractual term, and standard 90 day expiration upon termination of employment provisions. These options were modified to be immediately vested in full and to remove the 90 day expiration upon
termination of employment provision. Because the modified awards became fully vested and there was no future derived service period, all unamortized compensation expense related to the original grant and the additional compensation expense
attributable to the modification of the awards was recognized in full on the modification date. </font></p><p align="justify" style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">In addition,
the contractual provisions of outstanding stock options, other than the February 2008 full-round employee stock option grant, held by employees impacted by the workforce reduction were modified to extend the stock option expiration dates. Under the
original contractual provisions, outstanding stock options held by employees involved in a workforce reduction automatically become fully vested upon termination of employment and the stock options expire after the earlier of 90 days from
termination of employment or the remaining stock option contractual term. Under the modified terms, stock options for the impacted employees will expire after the earlier of three years from termination of employment or the remaining contractual
term. All unamortized compensation expense related to the original stock option awards plus the incremental compensation expense associated with the modifications will be recognized ratably from the modification date to the employees expected
termination date. The fair value of the modifications to all share-based awards was generally estimated using a lattice model. The total incremental pre-tax compensation expense associated with the modifications attributable to the 2009
restructuring plan was $11.0 million. </font></p>